Your browser doesn't support javascript.
loading
Descriptive evaluation of antibody responses to severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in plasma and gingival crevicular fluid in a nursing home cohort-Arkansas, June-August 2020.
Brown, Nicole E; Lyons, Amanda K; Schuh, Amy J; Stumpf, Megan M; Harcourt, Jennifer L; Tamin, Azaibi; Rasheed, Mohammad Ata Ur; Mills, Lisa; Lester, Sandra N; Thornburg, Natalie J; Nguyen, Kenny; Costantini, Veronica; Vinjé, Jan; Huang, Jennifer Y; Gilbert, Sarah E; Gable, Paige; Bollinger, Susan; Sabour, Sarah; Beshearse, Elizabeth; Surie, Diya; Biedron, Caitlin; Gregory, Christopher J; Clemmons, Nakia S; Whitaker, Brett; Coughlin, Melissa M; Seely, Kathryn A; Garner, Kelley; Gulley, Trent; Haney, Tafarra; Kothari, Atul; Patil, Naveen; Halpin, Alison Laufer; McDonald, L Clifford; Kutty, Preeta K; Brown, Allison C.
Afiliação
  • Brown NE; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Lyons AK; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Schuh AJ; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Stumpf MM; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Harcourt JL; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Tamin A; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Rasheed MAU; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Mills L; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Lester SN; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Thornburg NJ; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Nguyen K; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Costantini V; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Vinjé J; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Huang JY; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Gilbert SE; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Gable P; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Bollinger S; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Sabour S; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Beshearse E; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Surie D; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Biedron C; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Gregory CJ; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Clemmons NS; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Whitaker B; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Coughlin MM; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Seely KA; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Garner K; Arkansas Department of Health, Little Rock, Arkansas.
  • Gulley T; Arkansas Department of Health, Little Rock, Arkansas.
  • Haney T; Arkansas Department of Health, Little Rock, Arkansas.
  • Kothari A; Arkansas Department of Health, Little Rock, Arkansas.
  • Patil N; Arkansas Department of Health, Little Rock, Arkansas.
  • Halpin AL; Arkansas Department of Health, Little Rock, Arkansas.
  • McDonald LC; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Kutty PK; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Brown AC; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
Infect Control Hosp Epidemiol ; 43(11): 1610-1617, 2022 11.
Article em En | MEDLINE | ID: mdl-34802478
ABSTRACT

OBJECTIVE:

To characterize and compare severe acute respiratory coronavirus virus 2 (SARS-CoV-2)-specific immune responses in plasma and gingival crevicular fluid (GCF) from nursing home residents during and after natural infection.

DESIGN:

Prospective cohort.

SETTING:

Nursing home.

PARTICIPANTS:

SARS-CoV-2-infected nursing home residents.

METHODS:

A convenience sample of 14 SARS-CoV-2-infected nursing home residents, enrolled 4-13 days after real-time reverse transcription polymerase chain reaction diagnosis, were followed for 42 days. After diagnosis, plasma SARS-CoV-2-specific pan-Immunoglobulin (Ig), IgG, IgA, IgM, and neutralizing antibodies were measured at 5 time points, and GCF SARS-CoV-2-specific IgG and IgA were measured at 4 time points.

RESULTS:

All participants demonstrated immune responses to SARS-CoV-2 infection. Among 12 phlebotomized participants, plasma was positive for pan-Ig and IgG in all 12 participants. Neutralizing antibodies were positive in 11 participants; IgM was positive in 10 participants, and IgA was positive in 9 participants. Among 14 participants with GCF specimens, GCF was positive for IgG in 13 participants and for IgA in 12 participants. Immunoglobulin responses in plasma and GCF had similar kinetics; median times to peak antibody response were similar across specimen types (4 weeks for IgG; 3 weeks for IgA). Participants with pan-Ig, IgG, and IgA detected in plasma and GCF IgG remained positive throughout this evaluation, 46-55 days after diagnosis. All participants were viral-culture negative by the first detection of antibodies.

CONCLUSIONS:

Nursing home residents had detectable SARS-CoV-2 antibodies in plasma and GCF after infection. Kinetics of antibodies detected in GCF mirrored those from plasma. Noninvasive GCF may be useful for detecting and monitoring immunologic responses in populations unable or unwilling to be phlebotomized.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia / COVID-19 Tipo de estudo: Diagnostic_studies / Observational_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Infect Control Hosp Epidemiol Assunto da revista: DOENCAS TRANSMISSIVEIS / ENFERMAGEM / EPIDEMIOLOGIA / HOSPITAIS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Geórgia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia / COVID-19 Tipo de estudo: Diagnostic_studies / Observational_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Infect Control Hosp Epidemiol Assunto da revista: DOENCAS TRANSMISSIVEIS / ENFERMAGEM / EPIDEMIOLOGIA / HOSPITAIS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Geórgia